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 Chronic pain continues to be an insurmountable issue in recent times, particularly due to 
the lack of adequate knowledge as well as the unavailability of appropriate therapeutics that 
target it. The increasingly common prescription of opioids as medication to treat chronic pain has 
ultimately contributed to a national opioid epidemic. In response to this, several strides have 
been made by the Center for Disease Control and Prevention (CDC) to revise guidelines 
pertaining to opioid prescription for chronic pain. This project specifically focuses on identifying 
the mechanism of action of Physalin F, a natural compound isolated from the Physalis acutifolia 
(family: Solanaceae) herb, and previously demonstrated to exhibit antinociceptive effects in 
models of inflammatory pain, consistent with earlier reports of its anti-inflammatory and 
immunomodulatory activities. Through the use of calcium imaging, it was revealed that Physalin 
F had a significant inhibitory effect on voltage-gated calcium channels in dorsal root ganglion. In 
order to replicate these findings in-vivo, Physalin F was found to reverse mechanical allodynia in 
both paclitaxel-induced and spinal nerve ligation-induced neuropathic pain models, further 
elucidating its antinociceptive behavior. Experimentation results provided a better scope on 











Pain transduction is a necessary mechanism that the body requires to identify noxious 
stimuli that threaten homeostasis. Pain in itself is quite complex and can be largely categorized 
into nociceptive and neuropathic. This distinction is vital as both can be attributed to varying 
causes and pathways. Neuropathic pain, which is the focus of this paper, can be defined as pain 
associated with damage to the somatosensory system1. Although nociceptive pain offers 
evolutionary benefits, neuropathic pain largely tends to be maladaptive1. In addition to this, 
allodynia can be observed in most cases of neuropathic pain, which is the sensitization of pain 
achieved through the repeated stimulation of nociceptors in response to a non-painful stimulus. 
Neuropathic pain can be observed in instances of inflammation or metabolic disease such as 
diabetes7.  While there exists a variety of treatments available for nociceptive pain such as 
opioids and non-steroidal inflammatory drugs, chronic pain is much harder to manage, primarily 
due to a lack of knowledge surrounding the pathways that drive it1. This has led to the use of 
opioids as a course of pain management for neuropathic pain, which has contributed to the opioid 
epidemic currently overtaking North America. 
The role of prescription drugs in the lives of the average individual has seen a dramatic 
rise in the past two decades. The United States has been in the midst of a colossal opioid crisis 
for the past two decades, with approximately 2.4 million people contracting severe opioid 
disorder (OUD) attributed to an over-dependence on prescribed opioid medications, recreational 
heroine, or both6. Furthermore, opioid-related deaths reached a new high in 2013, surpassing 
deaths caused by motor vehicle accidents6. Since 2016, significant strides have been made by the 
U.S government to quell the escalating epidemic by making medication-assisted treatment such 
as methadone or naltrexone more accessible to the general population in order to treat an 
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overdose. However, the true obstacle lies within the pharmaceutical guidelines for the 
prescription of opioids. In response to the epidemic, the Center for Disease Control and 
Prevention (CDC) have revised the guidelines to lay emphasis on the avoidance of opioids in 
cases of chronic, non-cancerous, pain. In addition to this, the CDC recommends physicians to 
start opioid treatments with small dosages for patients who do qualify6. Although these 
guidelines do offer a decent foundation, there still exists a large space for improvement. A far 
more effective means to curb the opioid crisis, as acknowledged by the National Institute of 
Health, is to move away from opioid-related medications and instead identify alternate 
pharmacological targets through the development of non-opioid therapeutics for pain 
management5.  
In order to investigate potential therapeutic targets for chronic pain, it is important to first 
understand the process of pain conduction process. The chief players responsible for pain 
perception are the central nervous system (CNS) and peripheral nervous system (PNS). The PNS 
consists of the nerve fibers and ganglia that carry sensory information to the brain and the spinal, 
together known as the CNS, which works to integrate incoming sensory information and 
coordinate appropriate responses1. The fundamental mechanism of pain generation in response to 
noxious stimuli can be condensed into three basic steps: transduction, transmission, and 
modulation1. Transduction occurs when pain receptors, known as nociceptors, convert noxious 
stimuli into chemical signals. Such signals are then converted to electrical signals transmitted to 
the CNS via nerve fibers and, with the help of neurotransmitter, released at synaptic clefts. 
Modulation of these signals occurs at any part of the pathway, be it at the synaptic clefts or 
higher up in the CNS, through up or down-regulation. All three steps of the nociceptive pathway 




Figure 1: Schematic of nociceptive transmission involving the PNS and CNS, as well as a 
detailed depiction of synaptic transmission1 
 
Transmission of nociceptive signals from one neuron to another is mediated by 
neurotransmitter release at the axon terminal and involves an action potential, as depicted in 
Figure 2. Typically, the resting potential of a cell stands at nearly -70 mV, which implies that the 
axon of a neuron is negatively charged at rest. This can be attributed to the higher concentration 
of Na+ ions outside the cell than K+ cells within the cell. The movement of these ions is regulated 
via activation of ion channels. As a result, when the pain receptors of the body are exposed to a 
noxious stimulus, a potential is generated within the axon. The threshold potential, which is the 
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potential at which all sodium channels within the axon open, is reached and allows for sodium 
ions to enter the axon. This results in a dramatic rise in voltage within the cell to approximately 
40mV and depolarization of the axon. Once depolarization is achieved, an action potential is 
propagated through the axon to other neurons. Soon after, the voltage-gated Na+ channels are 
restored to their inactive state, the voltage-gated K+ channels are activated. This leads to an 
efflux of K+ ions, resulting in a dramatic fall of voltage within the cell and repolarization of the 
axon. Resting potential is at last achieved when the voltage-gated K+ channels are closed and the 
Na+/K+ transports reset the intracellular ion concentration7. 
The role of calcium ions and voltage-gated calcium channels becomes increasingly 
relevant once the action potential travels to the axon terminal. These specific channels play a key 
role in synaptic transmission and allow the pain stimuli to be transmitted to the adjacent neuron 
in the form of electrical impulses. The gap that exists between the presynaptic terminal of one 
neuron and the postsynaptic terminal of the adjacent neuron is known as the synaptic cleft. The 
synaptic cleft is involved in distinct chemical events responsible for impulse transmission. The 
arrival of the action at the presynaptic terminal triggers the depolarization of the presynaptic 
membrane via the activation of voltage-gated Na+ channels. This is quickly followed by the 
activation of voltage-gated Ca2+ channels, which allow Ca2+ influx into the axon terminal. The 
membrane depolarization elicits the exocytosis of neurotransmitters and Ca2+ ions into the 
synaptic cleft. The released neurotransmitters continue to bind to their corresponding ligand-
gated ion channels on the postsynaptic membrane, which permits the propagation of the action 
potential to the adjacent neuron7. 
This is pertinent to the project, as I attempt to induce depolarization in dorsal root ganglia 
of the spinal cord. Since depolarization is an important marker of pain transduction, it is an 
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excellent means to clinically observe experimental pain and test to see if the cells treated with the 
compound of interest inhibit depolarization either completely or to a significant degree. This 
inhibition indicates that the compound is successful at obstructing pain transduction and 
possesses potential antinociceptive properties. 
 
Figure 2: Components of an action potential1  
 
Physalin F (C28H30O10; molecular weight: 526.538 g/mol; Figure 3), a derivative of the 
herb Physalis acutifolia, have been previously established to have anti-nociceptive, anti-
inflammatory, and immunomodulatory properties3. This compound is known to inhibit the 
pathway of NF-KB activation; a prominent pathway responsible for the body’s inflammatory 
response. It is also associated with pro-inflammatory factors such as tumor necrosis factor 
(TNF)-alpha, interleukin-6, and interleukin-12, all of which are key components of the body’s 
mounting immune response3. While the compound’s link to immune and inflammatory pathways 
can be isolated, Physalin F's antinociceptive properties are largely unknown. Recent work 
submitted by Villarreal and collaborates suggests that Physalin F’s anti-nociceptive effects may 
be involved with pain transduction pathway, which was observed through its inhibition of 
writhing behavior generated using acetic-acid injections as well as inhibition of both early 
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nociceptive and late inflammatory stages of the formalin test5. Anti-nociceptive properties were 
also observed through the results of the tail-flick assay and hot-plate assay, which are indicative 
of the involvement of descending spinal pathways and supraspinal integrated responses 
respectively3. 
 
Figure 3: Chemical structure of Physalin F3 
 
MATERIALS AND METHODS 
Animals 
The cells used for all experimentation were dorsal root ganglia extracted from female 
Sprague-Dawley rats. The cells were extracted according to the protocol approved by the 
Institutional Animal Care and Use Committee of the College of Medicine at the University of 
Arizona4. The clinical procedures were conducted in conjunction with the ethical guidelines set 
forward by NIH and the International Association for the Study of Pain4. The cells were mounted 
on 15mM poly-D-lysine coverslips followed by incubation with either control or compound 
conditions for 24 hours prior to calcium imaging. 
 
Calcium Imaging 
Calcium signaling cascades play a significant role in the propagation of pain signals 
within the somatosensory system. A typical cell has a resting intracellular calcium concentration 
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of approximately 50-100 nM, which tends to rise nearly 10-100 times higher during transmission 
of electrical signals2. In order to keep track of changes in action potential in vitro is by 
monitoring the activation of voltage-gated calcium channels. For this purpose, calcium imaging 
was the primary imaging technique used to acquire both qualitative and quantitative data.  
Calcium imaging is advantageous as it provides both a qualitative visualization and quantitative 
estimation of the action potential within the neuronal cells. This specific imaging technique 
employs the use of a ratiometric fluorescent dye known as Fura-2AM, which binds to 
intracellular calcium ions and allows for quantitative measurements of calcium influx when cells 
are triggered with depolarizing stimuli. Since FURA-2AM is excitable at both 340 nm and 
380nm, the ratio of both wavelengths corresponds to the ratio of binding to unbound calcium 
ions within the cell2. The imaging was conducted with the help of an inverted microscope and 
the excitation light was produced by the Lamba-LS system4. Experiments were run for 8 minutes 
per coverslip, with cells exposed to either 40mM potassium chloride or 90mM potassium 
chloride, which work to activate either low or high activated voltage-gated calcium channels 
respectively. The two triggers are administered to the cells at 1 and 6 minutes for 15 seconds, 
and the peaks within these two time slots are measured and compared. Apart from the triggers, 
cells are exposed to Normal Tyrode's in order to maintain cell viability and resting potential. 
 
Paclitaxel-Induced Pain Model 
Adult male rats were treated with paclitaxel through an intraperitoneal administration of 
Paclitaxel. The rats were given a dosage of 2mg/kg every other day, adding up to a total dosage 
of 8mg/kg. The rats were then administered either saline (vehicle) or Physalin F (2ug/5 uL). 
Mechanical allodynia was achieved 10 days after initial paclitaxel administration4. Soon after, 
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paw withdrawal threshold of rats was measured before intrathecal injection of either saline 
(vehicle) or Physalin F, as well as an hour post injection for four successive hours. Paw 
withdrawal thresholds were then compared between the control rats and the Physalin F-treated 
rats. 
 
Spinal Nerve Ligation-Induced Pain Model 
Spinal nerve ligation was performed in order to induce mechanical allodynia. All adult male rats 
underwent intrathecal catheterization, 5 days after which all nerve procedures were conducted. 
Once the rats were anesthetized using 2% isoflurane in O2, the L5 and L6 spinal nerves were 
isolated and ligated to the dorsal root ganglia, while carefully preserving left hind paw function. 
The animals were given 7 days of recovery before experimentation4. Paw withdrawal threshold 
was then measured 15 days after surgery. 
 
RESULTS 
Calcium Imaging Analysis Data 
 
Figure 4: Average normalized response of the dorsal root ganglia when triggered with 40 mM 





Figure 5: Average normalized response of the dorsal root ganglia when triggered with 90 mM 
KCl and treated with varying concentrations of Physalin F 
 
 
A   B  
 
C   D  
Figure 6: Calcium imaging snapshots of dorsal root ganglia responding to buffers (A) Response 
of dorsal root ganglia to 40 mM KCl when treated with 0.1% DMSO (B) Response of dorsal root 
ganglia to 90 mM KCl when treated with 0.1% DMSO (C) Response of dorsal root ganglia to 40 
mM KCl when treated with Physalin F (D) Response of dorsal root ganglia to 90 mM KCl when 







Neuropathic Pain Model Data 
 
A        B   
Figure 7: Paclitaxel-induced neuropathic pain model (A) Paw withdrawal threshold measured in 
rats treated with 0.1% DMSO and Physalin F, both pre and post injection of treatment as well as 
for the subsequent 4 hours5 (B) Area under the curve measured for rodents treated with Physalin 
F as compared to DMSO within the window of allodynia reversal5 
 
 
A        B  
Figure 8: Spinal nerve ligation-induced neuropathic pain model data (A) Paw withdrawal 
threshold measured in rats treated with 0.1% DMSO and Physalin F. pre and post injection of 
treatment as well as for the subsequent 4 hours5 (B) Area under the curve measured for rodents 




Physalin F inhibits depolarization induced by calcium influx in dorsal root ganglia 
Prior to experimentation, Physalin F was proposed to have antinociceptive and anti-inflammatory 
effects3,5. However, the mechanism of action remains relatively unknown. This project aims to 
distinguish a distinct nociceptive pathway with a targeted focus on voltage-gated Ca2+ channels, 
which are highly expressed on dorsal root ganglia and involved in pain transmission. Since 
nociceptive properties were previously established, this project strived to identify an effective 
working concentration that achieved the most effective results. In order to test the effect of 
Physalin F on voltage-gated Ca2+ channels and measure calcium influx, both 40mM potassium 
chloride stimulus and 90 mM potassium chloride stimulus is used to induce depolarization by 
activating low- and high-voltage activated calcium channels respectively. For this reason, 
neurons were treated with either 0.1 % DMSO or varying concentrations of Physalin F (10nM, 
30nM, 100nM, 300nM, and 1uM). Figure 3 represents the average response of the DRGs to the 
40mM KCl when treated with Physalin F. According to the results, DRGs treated with 1uM 
Physalin F showed nearly a 50% decrease in calcium-induced depolarization as compared to the 
control. This indicates potential inhibition of low-voltage gated calcium channels and would 
require a further in-depth investigation for the replication of acquired results. Figure 4 represents 
the average response of DRGs to 90 mM KCl when treated with multiple Physalin F 
concentrations. As seen in the figure, DRGs treated with 1uM Physalin F once again exhibited 
significantly decreased depolarization (~20%) elicited by calcium ion influx as compared to 
control. This also suggests potential inhibition of high voltage-activated Ca2+ channels by 
Physalin F and offers a route for further research. Figure 5 represents a qualitative depiction of 
the results as it presents FURA-2AM-mediated calcium imaging of DRGS. Figure 5a and 5b 
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describe DRG depolarization when treated with 0.1% DMSO and triggered by 40mM KCl and 
90mM KCl respectively. Neurons presenting as purple represent a typical resting potential while 
neurons presenting as green indicated depolarization. As expected in the control, 90mM KCl 
elicits a more exaggerated response than 40mM KCl due to differences in voltage activation. 
Figure 5C and 5D describe DRGs treated with 1uM Physalin F and triggered with 40mM KCl 
and 90mM KCl respectively. Qualitatively, 1uM appear to inhibit depolarization as compared to 
the control due to the diminished presence of DRGs imaged as green. These results indicate that 
Physalin F has a significant effect on voltage-gated Ca2+ channels in neurons. 
 
Physalin F exhibits antinociceptive behavior in Paclitaxel-induced pain model 
Calcium imaging helped reveal that voltage-gated Ca2+ channels are a good therapeutic target for 
Physalin F. In addition to this, 1uM Physalin F was established as an appropriate working 
concentration for further experimentation. The subsequent route of experimentation was to test 
the efficacy of Physalin F's antinociceptive properties in-vivo. This was first accomplished 
through the use of chemotherapy-induced neuropathic pain model. In this model, mechanical 
allodynia was induced through the administration of paclitaxel, followed by intrathecal injection 
of either saline (vehicle) or Physalin F, as described in the methods. According to figure 7A, the 
results indicate a significantly higher paw withdrawal threshold in rats treated with Physalin F as 
compared to the control rats post-injection. This increase in threshold was also sustained for four 
successive hours, indicating significant nociceptive behavior. Figure 7B represents this data 
through an area under the curve graph, which signifies a significantly higher paw withdrawal 
threshold observed in rats treated with Physalin F as compared to the control rats.  
Physalin F exhibits antinociceptive behavior in SNL-induced pain model 
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Physalin F was also tested through an SNL-induced pain model, which involves partially 
disrupting the sciatic nerve5. Once allodynia was achieved, the rats were treated with either 
saline (vehicle) or Physalin F. As shown in figure 7A, the rats treated with Physalin F showed a 
dramatic reversal of allodynia within a 4-hour period as compared to the control rats. These 
results were mirrored in figure 7B through an area under the curve graph which indicated a 
significantly higher paw withdrawal threshold among the Physalin F treated rats when compared 
to control. These results help conclude that Physalin F has a significant inhibitory effect on 
experimental neuropathic pain. 
 
CONCLUSION 
 Experimentation helped revealed that Physalin F indeed had a significant effect on the 
voltage-gated calcium channels and exhibits antinociceptive behavior both in vitro and in vivo. 
Calcium imaging results revealed significantly lower responses presented by the dorsal root 
ganglia when treated with a 1uM concentration of Physalin F, as compared to the control. These 
results were reflected both quantitatively (Figure 4 and 5) and qualitatively (Figure 6). These 
results are substantial because of the role of calcium signaling in synaptic transmission. By 
targeting voltage-gated calcium channels, Physalin F affects pain transmission. The compound 
also reaffirmed antinociceptive behavior through both paclitaxel-induced and spinal nerve 
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